Prostate-specific membrane antigen (PSMA) is a membrane protein that is overexpressed
manifold in prostate cancer and provides an attractive target for therapy. PSMA ADC is an …

Prostate-specific membrane antigen (PSMA) is the prototypic cell-surface marker of prostate
cancer and provides an attractive target for monoclonal antibody (mAb) targeted therapies …

Background Prostate‐specific membrane antigen (PSMA) is a well‐characterized target that
is overexpressed selectively on prostate cancer cells. PSMA antibody‐drug conjugate (ADC) …

Simple Summary Currently, there is no effective treatment that can cure metastatic prostate
cancer. Various pros-tate specific membrane antigen (PSMA)-targeted radioimaging and …

BACKGROUND It is timely and important to develop new treatment modalities for advanced
prostate cancer, because even the newly FDA approved treatments, despite providing …

Prostate-specific membrane antigen (PSMA) is a promising target for the treatment of
advanced prostate cancer (PC) and various solid tumors. Although PSMA-targeted …

MLN2704 is an antibody-chemotherapeutic conjugate designed to target prostate-specific
membrane antigen (PSMA). PSMA is a transmembrane receptor whose expression is …

Background Prostate‐specific membrane antigen (PSMA) is a well‐established therapeutic
and diagnostic target overexpressed in both primary and metastatic prostate cancers. PSMA …

Cell-surface markers of prostate cancer 3. PSMA as a target for cancer therapy 4. Antibody-
drug conjugate chemistries 5. Preclinical findings 5.1. PSMA ADC 5.2. MLN2704 5.3 …

BACKGROUND Antibody–drug conjugates (ADCs) are an emerging class of cancer
therapies that have demonstrated favorable activity both as single agents and as …